Two separate health policy battles — drug trial oversight and peptide access — share a pattern that is becoming hard to miss: political momentum is outrunning the institutional safeguards built into American health policy.
Congress is demanding Merck and AbbVie explain their clinical trial operations in China by July 17, and FDA career scientists are publicly contradicting Health and Human Services Secretary Robert F. Kennedy Jr. over his push to expand access to peptides, a class of injectable compounds used in longevity clinics and hormone therapies. The events sit in different agencies and concern different products, but they share a mechanism that is becoming harder to miss: political velocity is outrunning the institutional safeguards normally built into American health policy.
The House Select Committee on the Chinese Communist Party has opened a national-security investigation into whether Merck and AbbVie conducted clinical trials in China that may have aided the country's military biotech capability, according to reporting by Reuters via STAT's Pharmalittle morning roundup. Lawmakers have given the two drugmakers until July 17 to produce records on their due diligence, data protection processes, and trial-site standards, with a particular focus on the Xinjiang region in northwest China and on military hospitals, per regional reporting that drew on the underlying committee letters. Trial sites are the hospitals and clinics where drugs are tested on patients.
Markets reacted quickly. CNBC's live market coverage on June 29 noted Merck shares fell roughly 0.6 percent and AbbVie shares about 0.5 percent intraday after Reuters broke the investigation, while broader indices opened flat. The committee investigation is not the only legislative vehicle in play: House Select Committee Chairman John Moolenaar and Representative Debbie Dingell have introduced companion legislation aimed at preventing the offshoring of U.S. biotechnology to China, giving the Merck and AbbVie letters a broader political frame.
That frame is part of a wider federal stack. A June 2026 client alert from the law firm Foley Hoag catalogs recent activity by the Committee on Foreign Investment in the United States, export controls, and restrictions in the spirit of the BIOSECURE Act, all aimed at China-linked biotech investment and collaboration. The two drugmakers are not accused of violating any of these tools yet. The committee is asking whether their trial sites became part of a research ecosystem that has military applications, whether the companies knew it, and whether the U.S. government should have done more to prevent it.
A different kind of pushback is unfolding inside the FDA. Kennedy has signaled he wants to loosen restrictions on peptides, which are sold through compounding pharmacies that custom-mix drugs for individual patients and through longevity and wellness clinics. Reporting by The Guardian and NBC News in late June tied that push to the longevity-clinic ecosystem and to the Health Secretary's stated interest in expanding therapeutic access.
Career scientists at the FDA have publicly pushed back, posting findings that there is not enough evidence to allow certain peptides to be compounded, a position that directly contradicts the political leadership's direction. The newly seated advisory panel reviewing these questions is reported to include at least seven members with peptide-business or peptide-clinic ties and one member who is the son of a congresswoman who pressed Kennedy to convene the panel in the first place. That conflict-of-interest texture does not mean the panel's eventual conclusions are wrong, but it does mean readers should watch who is in the room when those conclusions are written.
The two items share three structural features. Both rely on a deadline, hearing, or advisory vote running on a faster clock than the underlying scientific or security review. Both feature career public servants, committee investigators and FDA reviewers, pushing back against a direction set by political appointees or political momentum. Both expose the gap between what political actors want to move quickly and what the existing institutional review process is set up to catch.
Three clocks are now running. Merck and AbbVie have until July 17 to respond to the congressional letters; what they disclose, and what the committee decides to do with partial answers, will set the political temperature for any companion legislation. The FDA Pharmacy Compounding Advisory Committee is scheduled to meet July 23 and 24; that meeting is the most visible venue for the peptide fight, and the conflict-of-interest disclosures from seated panelists will be read closely. The peptide policy itself is still in a "weighing" posture, not a final posture; any forward claim that the FDA has loosened, or is about to loosen, restrictions should be treated as Kennedy's stated direction rather than settled rule.
The question worth holding is not whether Congress or the FDA is right in either individual case. It is whether the institutions built to slow down consequential health and security decisions are still being allowed to do their job, or whether political momentum has become the default pace.